RU2007120643A - METHOD FOR PREVENTION OF RECURRENCE OF CHRONIC VIRAL HEPATITIS AFTER ACHIEVEMENT OF VIROLOGICAL REMISSION - Google Patents
METHOD FOR PREVENTION OF RECURRENCE OF CHRONIC VIRAL HEPATITIS AFTER ACHIEVEMENT OF VIROLOGICAL REMISSION Download PDFInfo
- Publication number
- RU2007120643A RU2007120643A RU2007120643/14A RU2007120643A RU2007120643A RU 2007120643 A RU2007120643 A RU 2007120643A RU 2007120643/14 A RU2007120643/14 A RU 2007120643/14A RU 2007120643 A RU2007120643 A RU 2007120643A RU 2007120643 A RU2007120643 A RU 2007120643A
- Authority
- RU
- Russia
- Prior art keywords
- courses
- recurrence
- prevention
- months
- dose
- Prior art date
Links
Abstract
Способ профилактики рецидива хронического вирусного гепатита С после достижения первичной вирусологической ремиссии с помощью стандартной интерфероновой терапии, отличающийся тем, что после интерферонотерапии применяют Ронколейкинв дозе 500 мг внутрь в 200 мл воды через 2 ч после ужина, двумя курсами по 5-10 раз через день или 2 раза в неделю, после третьего приема препарата Ронколейкинбольной принимает Ликопид 10 мг ежедневно 1 раз в день в течение 10 дней, интервал между курсами 2 месяца, осуществляя контроль общего анализа крови, функциональных проб печени 1 раз в месяц и иммунограммы 1 раз в 3 месяца, при необходимости курсы лечения повторяются весной и осенью.A method for the prevention of recurrence of chronic viral hepatitis C after achieving primary virological remission using standard interferon therapy, characterized in that after interferon therapy, a dose of 500 mg Roncoleukin is used orally in 200 ml of water 2 hours after dinner, in two courses of 5-10 times every other day or 2 times a week, after the third dose of the drug, Roncoleukin patient takes Likopid 10 mg daily 1 time per day for 10 days, the interval between courses is 2 months, monitoring the general blood test, functionally liver samples 1 time per month and immunograms 1 time in 3 months, if necessary, treatment courses are repeated in spring and autumn.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2007120643/14A RU2348412C1 (en) | 2007-06-01 | 2007-06-01 | Method of prevention of chronic viral hepatitis type c recurrent after virus remission |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2007120643/14A RU2348412C1 (en) | 2007-06-01 | 2007-06-01 | Method of prevention of chronic viral hepatitis type c recurrent after virus remission |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2007120643A true RU2007120643A (en) | 2008-12-10 |
RU2348412C1 RU2348412C1 (en) | 2009-03-10 |
Family
ID=40528526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007120643/14A RU2348412C1 (en) | 2007-06-01 | 2007-06-01 | Method of prevention of chronic viral hepatitis type c recurrent after virus remission |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2348412C1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
GB2515941A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
EA201490836A1 (en) | 2011-10-21 | 2014-11-28 | Эббви Инк. | COMBINATION TREATMENT (FOR EXAMPLE, WITH ABT-072 OR ABT-333) WITH THE HELP OF DAA FOR USE WHEN TREATING HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
RU2477478C1 (en) * | 2011-11-23 | 2013-03-10 | Олег Владимирович Князев | Method of assessing clinical effectiveness in inflammatory intestinal diseases |
CN109689063A (en) | 2016-04-28 | 2019-04-26 | 埃默里大学 | Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses |
-
2007
- 2007-06-01 RU RU2007120643/14A patent/RU2348412C1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2348412C1 (en) | 2009-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ferenci et al. | Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy | |
RU2007120643A (en) | METHOD FOR PREVENTION OF RECURRENCE OF CHRONIC VIRAL HEPATITIS AFTER ACHIEVEMENT OF VIROLOGICAL REMISSION | |
RU2365372C2 (en) | Cyclic protein tyrosine kinase inhibitors | |
RU2007132181A (en) | ANTI-CANCER MEDICINE CONTAINING α, α, α-TRIFTORTIMIDINE AND A THIMIDINFOSPHORILYLASE INHIBITOR | |
ATE430574T1 (en) | HERBAL-BASED MEDICATION FOR THE TREATMENT OF HEPATITIS C | |
DK1750716T3 (en) | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin | |
RU2010133489A (en) | USE OF GAMMA SECRETASE INHIBITORS FOR TREATMENT OF CANCER | |
RU2014122154A (en) | COMPOSITIONS SUITABLE FOR THE TREATMENT OF VIRAL DISEASES | |
RU2010138887A (en) | TREATMENT OF MALIGNANT NEW FORMATION USING VIRUSES AND CAMPTOTECINS | |
Shimizu et al. | Hypophosphatemia in patients with hepatitis B virus infection undergoing long‐term adefovir dipivoxil therapy | |
RU2009101026A (en) | APPLICATION OF THYMOSINE-ALPHA-1 FOR PRODUCING A MEDICINE FOR TREATING MALIGNANT MELANOMA IN STAGE IV | |
EA200600377A1 (en) | NEW COMPOSITION | |
RU2010101634A (en) | METHOD FOR OPTIMIZING TREATMENT OF CHRONIC MYELOLEukOSIS BY ABI TRIROZINKINASE INHIBITORS | |
RU2005134430A (en) | METHOD FOR BASIC TREATMENT OF CHRONIC VIRAL HEPATITIS C | |
RU2013120345A (en) | NEW METHODS FOR TREATING INFECTIONS CAUSED BY HEPATITIS C VIRUS | |
Kim et al. | Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells | |
WO2017177515A1 (en) | Application of 4-hydroxy salicylanilide in preparation of anti-myeloma or anti-lymphoma drugs | |
RU2008109649A (en) | PEG-IFNα and Ribavirin for the Treatment of Hepatitis B Virus | |
CN100344284C (en) | Use of Abidol in preparing medicines for treating and preventing SARS virus | |
WO2022019742A1 (en) | Pharmaceutical package for preventing and/or treating covid-19 disease and use of same | |
Verhaz et al. | Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir±Dasabuvir Regimen in Haemodialysis Patients With Hepatitis C Virus Infection: A Case Series | |
CN114515338B (en) | Pharmaceutical composition for treating viral hepatitis | |
Arora | Erlotinib-induced Hepatotoxicity—Clinical Presentation and Successful Management: A Case Report | |
RU2013148539A (en) | ALISPORIVIR FOR TREATMENT OF HEPATITIS C VIRUS INFECTION | |
Verhaz et al. | Učinkovitost i sigurnost kombinacije ombitasvir/paritaprevir/ritonavir±dasabuvir u bolesnika na hemodijalizi s infekcijom virusom hepatitisa C: prikaz serije bolesnika |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20090602 |